So, in essence, the $3.5 mill of the cap raise for the waiver study, simply need not be spent. BARDA will fund the study. And if the study has some cost overrun (up to $8 mill total) then BARD will fund that as well.
The big amount for product development, is.... big
Talk about lining up the ducks! wow! But, again, how does one 'value' the Company. If the company is operating cash flow positive AND ebitda profitable then surely the market cap must rise.
Ann: Lumos and BARDA Partner to Support FebriDx CLIA Waiver Study, page-94
Add to My Watchlist
What is My Watchlist?
